Poolbeg Pharma launches AI programme with Eurofins Genomics

London-based infectious disease pharmaceutical company, Poolbeg Pharma, has announced their deal with testing and support specialist, Eurofins Genomics, according to Proactive Investors.

CEO of Poolbeg Pharma, Jeremy Skillington, says that the aim of this partnership is to complete the next-generation RNA sequencing of respiratory syncytial virus (RSV) disease progression samples from human viral challenge studies.

Poolbeg Pharma plc (LON:POLB) is a clinical stage infectious disease pharmaceutical company, with a novel capital light clinical model which enables us to develop multiple products faster and more cost effectively than the traditional biotech model. 

Click to view all articles for the EPIC:
Or click to view the full company profile:
Share on facebook
Facebook
Share on twitter
Twitter
Share on linkedin
LinkedIn

More articles like this

Introduction to Dr Elaine Sullivan – Scientific Advisor Board

Poolbeg Pharma plc (LON:POLB) is a clinical stage infectious disease pharmaceutical company, with a novel capital light clinical model which enables us to develop multiple products faster and more cost effectively than the traditional biotech model. 

Poolbeg Pharma signs an Option Agreement to licence MelioVac

Poolbeg Pharma plc (LON:POLB), a clinical stage infectious disease pharmaceutical company with a capital light clinical model, has signed an Option Agreement to licence MelioVac, a vaccine for melioidosis, with University College Dublin (‘UCD’) and its inventor, Associate Professor

Building a leading infectious diseases company

Infectious diseases have, over the last decade, been a relatively under-funded area of pharmaceutical research with ‘Big Pharma’ deprioritisingR&D in this space. But then an unprecedented global pandemic broughtabout devastating human and economic damage, the impact of which

POLB 001 update from Poolbeg Pharma

Poolbeg Pharma plc (LON:POLB) is a clinical stage infectious disease pharmaceutical company, with a novel capital light clinical model which enables us to develop multiple products faster and more cost effectively than the traditional biotech model. 

Covid, cold or flu?

As viruses return with a vengeance, doctors are struggling to diagnose patients’ coughs and runny noses. In 1918 a deadly influenza pandemic swept the world, and doctors had a tough time diagnosing it. The symptoms were so unusual